Literature DB >> 16043870

Prolactins are natural inhibitors of angiogenesis in the retina.

Jorge Aranda1, José C Rivera, Michael C Jeziorski, Juan Riesgo-Escovar, Gabriel Nava, Fernándo López-Barrera, Hugo Quiróz-Mercado, Peter Berger, Gonzalo Martínez de la Escalera, Carmen Clapp.   

Abstract

PURPOSE: Disruption of the normally antiangiogenic environment of the retina leads to aberrant angiogenesis, the major cause of vision loss throughout the world. Prolactin (PRL), the hormone originally associated with milk production, can be proteolytically processed to 16K-PRL, a 16 kDa N-terminal PRL fragment with potent antiangiogenic and vasoconstrictive actions. This study was conducted to determine whether 16K-PRL is found naturally in the retina and plays a role in angiogenesis and vasodilation.
METHODS: Expression of PRL mRNA in rat retina was determined by RT-PCR and in situ hybridization. Western blot was used to examine the expression of PRL and derived fragments in retinal homogenates. The role of PRL and 16K-PRL in the retina was studied by intravitreal injection of either antibodies against PRL or small interfering RNAs (siRNA), to suppress expression of retinal PRL mRNA.
RESULTS: Rat retina expressed PRL mRNA in the outer nuclear, outer plexiform, inner nuclear, and ganglion cell layers. Both full-length PRL and N-terminal 16K-PRL were detected in retinal homogenates by polyclonal and monoclonal antibodies. The intravitreal injection of antibodies able to neutralize the actions of 16K-PRL increased the number of retinal blood vessels and capillary area by threefold. Furthermore, siRNA-mediated inhibition of PRL mRNA increased retinal neovascularization threefold and resulted in a significant increase in vasodilation.
CONCLUSIONS: These results demonstrate that PRL is synthesized and cleaved to antiangiogenic 16K-PRL by retinal tissue and that these molecules play a key role in preventing angiogenesis in the healthy retina.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043870     DOI: 10.1167/iovs.05-0173

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  25 in total

1.  Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity.

Authors:  Luz Consuelo Zepeda-Romero; Miguel Vazquez-Membrillo; Elva Adan-Castro; Francisco Gomez-Aguayo; Jose Alfonso Gutierrez-Padilla; Eusebio Angulo-Castellanos; Juan Carlos Barrera de Leon; Cesareo Gonzalez-Bernal; Manuel Alejandro Quezada-Chalita; Alonso Meza-Anguiano; Nundehui Diaz-Lezama; Gonzalo Martinez de la Escalera; Jakob Triebel; Carmen Clapp
Journal:  Pediatr Res       Date:  2016-11-14       Impact factor: 3.756

Review 2.  Diabetic retinopathy and pregnancy.

Authors:  Nicola Pescosolido; Orazio Campagna; Andrea Barbato
Journal:  Int Ophthalmol       Date:  2014-01-31       Impact factor: 2.031

3.  CTGFsiRNA ameliorates retinal cells apoptosis in streptozotocin-induced diabetic rats.

Authors:  Hong-Wei Yang; Xiao-Long Chen; Zhe-Li Liu; Jie Liu; Li-Min Bu
Journal:  Int J Ophthalmol       Date:  2010-06-18       Impact factor: 1.779

4.  Transcriptomic analysis across nasal, temporal, and macular regions of human neural retina and RPE/choroid by RNA-Seq.

Authors:  S Scott Whitmore; Alex H Wagner; Adam P DeLuca; Arlene V Drack; Edwin M Stone; Budd A Tucker; Shemin Zeng; Terry A Braun; Robert F Mullins; Todd E Scheetz
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

Review 5.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

6.  High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins.

Authors:  Edith Arnold; José C Rivera; Stéphanie Thebault; Daniel Moreno-Páramo; Hugo Quiroz-Mercado; Andrés Quintanar-Stéphano; Nadine Binart; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

7.  Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.

Authors:  Raul Velez-Montoya; Carmen Clapp; Jose Carlos Rivera; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado
Journal:  Clin Ophthalmol       Date:  2010-09-07

8.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

9.  Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.

Authors:  Celina García; Jorge Aranda; Edith Arnold; Stéphanie Thébault; Yazmín Macotela; Fernando López-Casillas; Valentín Mendoza; Hugo Quiroz-Mercado; Hebert Luis Hernández-Montiel; Sue-Hwa Lin; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

10.  Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).

Authors:  Carmen Aceves; Pablo García-Solís; Omar Arroyo-Helguera; Laura Vega-Riveroll; Guadalupe Delgado; Brenda Anguiano
Journal:  Mol Cancer       Date:  2009-06-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.